Johns Hopkins Berman Institute of Bioethics | WYPR

Johns Hopkins Berman Institute of Bioethics

Johns Hopkins University

And now, it’s Midday on Ethics.

The coronavirus doesn’t only pose epidemiological challenges. It poses ethical dilemmas as well, particularly as governments grapple with containing the epidemic.

Whenever science and health news raises potential ethical concerns, we turn to Dr. Jeffrey Kahn, who joins me now in Studio A.

Dr. Kahn is the director of the Johns Hopkins Berman Institute of Bioethics. He is one of the co-editors of The Oxford Handbook of Public Health Ethics.  And he has a recurring role in “Unnatural Selection” — a four-part series on Netflix about the possible uses of gene editing.

We livestreamed this conversation on the WYPR Facebook page.  Click here to watch. 

COURTESY OF JOHNS HOPKINS UNIVERSITY

If you are a person with a condition that requires millions of dollars worth of pharmaceuticals, even having health insurance may not be enough.  Almost no individual can afford that kind of treatment, and increasingly, employer or union-based insurance plans can’t afford it either.  Is the high cost of some of these medications due solely to the greed of big Pharma?  In a word, no.  There are many reasons for why drugs cost so much. 

Tom is joined in studio by Dr. Jeffrey Kahn, the Director of the Johns Hopkins Berman Institute of Bioethics.  In addition to being a regular guest on this program, he is one of the co-editors of a new book: The Oxford Handbook of Public Health Ethics, published just a couple of weeks ago by Oxford University Press.  

Credit: Markus Grossalber / Flickr / Creative Commons
Markus Grossalber / Flickr / Creative Commons

The number of medical drugs in short supply has tripled since 2007. What can be done to lower the impact on patients?  We ask Dr. Yoram Unguru from the Johns Hopkins Berman Institute of Bioethics.